NGL Fine-ChemNSE:NGLFINE +9.14%78 Days Payable is 83.15 as of Mar. 2026, which is 16% below its 10-year median of 98.91. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,815.72 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 922 Drug Manufacturers companies, NGL Fine-Chem ranks better than 54.12% on this metric.
The historical rank and industry rank for NGL Fine-Chem's Days Payable or its related term are showing as below:
NSE:NGLFINE'
s Days Payable Range Over the Past 10 Years
Min: 80.3 Med: 98.91 Max: 151.16
Current: 98.41
During the past 13 years, NGL Fine-Chem's highest Days Payable was 151.16. The lowest was 80.30. And the median was 98.91.
NSE:NGLFINE's Days Payable is ranked better than 54.12% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NSE:NGLFINE: 98.41
NGL Fine-Chem's Days Payable
declined
from Mar. 2025 (109.80) to Mar. 2026 (83.15).
It may suggest that NGL Fine-Chemaccelerated paying its suppliers.
NGL Fine-Chem Days Payable Related Terms
NGL Fine-Chem Days Payable Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Days Payable distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
NGL Fine-Chem's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGL Fine-Chem (NSE:NGLFINE) has a Days Payable of 83.15 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NGL Fine-Chem and its competitors. This is 16% below median its historical median of 98.91. Over the past decade, NGL Fine-Chem's Days Payable has ranged from 80.30 to 151.16. According to the industry distribution chart, NGL Fine-Chem ranks #423 out of 922 companies in the Drug Manufacturers industry, placing it in the top 45.9%.
Is NGL Fine-Chem's Days Payable too high?
NGL Fine-Chem's current Days Payable of 83.15 is 16% below median its 10-year median of 98.91. Over the past 10 years, this metric has ranged from a low of 80.30 to a high of 151.16. The Drug Manufacturers industry median Days Payable is 90.84. NGL Fine-Chem's value of 83.15 is 8.5% below this industry median. Based on the distribution chart, NGL Fine-Chem ranks #423 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #423 out of 922 companies for Days Payable. This puts NGL Fine-Chem in the upper half of its industry. The industry median Days Payable is 90.84. NGL Fine-Chem's value of 83.15 is 8.5% below this benchmark. Historically, NGL Fine-Chem's own Days Payable has ranged from 80.30 to 151.16 over the past decade. While the company's 10-year median is 98.91 vs. the industry median of 90.84, NGL Fine-Chem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current Days Payable of 83.15 is 8.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current Days Payable is 83.15, which is 16% below median its own 10-year median of 98.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,815.72, compared to a current price of ₹3,206.00 — trading 13.9% above its estimated fair value. The current Days Payable is 83.15, which is 16% below median its 10-year median of 98.91 and 8.5% below the Drug Manufacturers industry median of 90.84. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current Days Payable is 83.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹3,206.00 is trading 13.9% above its estimated GF Value™ of ₹2,815.72.
GuruFocus considers NGL Fine-Chem to be Modestly Overvalued.
Key valuation signals for NSE:NGLFINE:
Days Payable: 83.15 (16% below median its 10-year median of 98.91)
GF Value™: ₹2,815.72 vs. price of ₹3,206.00 (13.9% above fair value)
Industry Position: 8.5% below the Drug Manufacturers median (#423 of 922)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
